Abraxane Plus Pembrolizumab Targets Advanced Bladder Cancer in Cisplatin-Ineligible Patients
A completed phase 2 trial tested nab-paclitaxel combined with the checkpoint inhibitor pembrolizumab in patients with advanced urothelial cancer who cannot tolerate cisplatin.
Summary
Many patients with advanced urothelial (bladder and urinary tract) cancer are ineligible for standard cisplatin-based chemotherapy due to poor kidney function or other health issues, leaving them with limited treatment options. This phase 2 clinical trial explored whether combining abraxane (nab-paclitaxel), a chemotherapy drug, with pembrolizumab, an immune checkpoint inhibitor that helps the immune system attack cancer cells, could offer a viable alternative. Conducted at the University of Michigan Rogel Cancer Center, the study enrolled patients in a two-stage design, administering both drugs intravenously on a 21-day cycle schedule. The trial has been completed, though full results are not yet publicly available from the abstract alone. This combination approach represents a meaningful effort to expand treatment access for a vulnerable cancer population.
Detailed Summary
Advanced urothelial carcinoma — cancer arising from the lining of the bladder, ureters, or urethra — carries a poor prognosis, particularly for patients who cannot receive cisplatin-based chemotherapy. Cisplatin ineligibility is common, affecting a substantial portion of patients due to impaired kidney function, hearing loss, neuropathy, or poor performance status. These individuals historically face a narrower set of effective treatment options, making the development of alternative regimens a pressing clinical need.
This phase 2, single-arm, two-stage study investigated a novel combination of abraxane (nab-paclitaxel) and pembrolizumab, an anti-PD-1 checkpoint inhibitor, in cisplatin-ineligible patients with advanced urothelial cancer. Abraxane is an albumin-bound form of the chemotherapy agent paclitaxel, designed to improve drug delivery and reduce some side effects compared to standard paclitaxel. Pembrolizumab has established efficacy in urothelial cancer as a single agent, and the rationale for combination is that chemotherapy may increase tumor antigen exposure, potentially enhancing the immune response triggered by checkpoint blockade.
Patients received pembrolizumab intravenously on day 1 of each 21-day cycle, with abraxane administered on both day 1 and day 8. Treatment continued until disease progression or unacceptable toxicity. The two-stage design is a standard approach to allow early stopping if the regimen shows insufficient efficacy or excessive harm in the first stage.
The trial, sponsored by the University of Michigan Rogel Cancer Center, has been completed. Specific efficacy and safety outcomes — including response rates, progression-free survival, and toxicity profiles — are not available from the abstract alone and await formal publication.
This study is clinically significant because it directly addresses an underserved patient population. If the combination proves effective and tolerable, it could expand first-line or subsequent treatment options for patients currently left with few viable regimens.
Key Findings
- Phase 2 trial combined nab-paclitaxel (abraxane) with pembrolizumab in cisplatin-ineligible advanced urothelial cancer patients.
- Treatment was delivered on a 21-day cycle: pembrolizumab on day 1, abraxane on days 1 and 8.
- Study used a two-stage design to allow early termination if safety or efficacy thresholds were not met.
- Trial is completed; full efficacy and safety results are pending formal publication.
- Targets a high-need population: cisplatin-ineligible patients have significantly limited standard treatment options.
Methodology
This was a phase 2, single-arm, two-stage study enrolling cisplatin-ineligible patients with advanced urothelial carcinoma at the University of Michigan Rogel Cancer Center. Participants received pembrolizumab IV on day 1 and abraxane IV on days 1 and 8 of each 21-day cycle, continuing until progression or unacceptable toxicity. The two-stage design allows interim analysis to determine whether enrollment should continue based on early outcomes.
Study Limitations
This summary is based on the abstract and trial registration only, as the full study data are not publicly available; specific response rates, survival outcomes, and safety profiles cannot be reported. The single-arm design without a comparator group limits the ability to draw definitive conclusions about superiority over existing options. As a phase 2 study, findings will require confirmation in larger, randomized trials before practice-changing recommendations can be made.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: